tbuckley/cabot-search huggingface dataset:
Abstract P4-21-36: Splenic enlargement and bone marrow hyperplasia in patients receiving trastuzumab-emtansine for metastatic breast cancer
Authors: M Kosmin, A Makris, N Jawad, D Miles, AR Padhani
Journal: Cancer Research (2017)

Abstract Introduction Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate used for treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. An association between T-DM1 and splenic enlargement was noted anecdotally on sequential whole-body MRI (WB-MRI) examinations. A retrospective analysis of WB-MRI examinations of patients on T-DM1 was undertaken to investigate the hypothesis that an increase in splenic volume is due to either a generalised hyperplasia of the bone marrow and reticulo-endothelial system and/or an increase in portal venous pressure. Methods 12 patients underwent 29 serial WB-MRIs before and during T-DM1 therapy. Splenic volume, portal vein diameter, bone marrow muscle-normalised signal intensity (nSI), water diffusivity (apparent diffusion coefficient, ADC) and fat fraction were measured. Changes in splenic volume were analysed, and correlations between the measured variables were obtained. Results An increase in splenic volume was observed in 92% of patients. Mean splenic volume increased from 144cm3 (95%CI 110-177cm3) to 209cm3 (95%CI 161-257cm3) on T-DM1 therapy (p=0.006). Increase in splenic volume correlated with treatment duration (r2=0.71). Increase in normal bone marrow signal was seen (nSI 3.5 to 4.8, p=0.12), along with a decrease in fat fraction (64.3% to 57.3%, p=0.12), and reduced ADC (655µm2/s to 543µm2/s, p=0.11). No consistent changes to portal vein diameter were seen. Discussion An increase in splenic volume was consistently observed in patients on T-DM1 therapy. This was unrelated to portal vein changes but correlated with bone marrow hyperplasia. Caution should be applied when assessing metastatic disease in bone to avoid incorrectly attributing T-DM1-related changes in normal bone marrow to disease progression. Citation Format: Kosmin M, Makris A, Jawad N, Miles D, Padhani AR. Splenic enlargement and bone marrow hyperplasia in patients receiving trastuzumab-emtansine for metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-36.
Calf muscle strain injuries in sport: a systematic review of risk factors for injury
Authors: Brady Green, Tania Pizzari
Journal: British Journal of Sports Medicine (2017)

Objective To systematically review the literature to identify risk factors for calf strain injury, and to direct future research into calf muscle injuries. Design Systematic review Data sources Database searches conducted for Medline, CINAHL, EMBASE, AMED, AUSPORT, SportDiscus, PEDro and Cochrane Library. Manual reference checks, ahead of press searches, citation tracking. From inception to June 2016. Eligibility criteria for selecting studies Studies evaluating and presenting data related to intrinsic or extrinsic risk factors for sustaining future calf injury. Results Ten studies were obtained for review. Subjects across football, Australian football, rugby union, basketball and triathlon were reported on, representing 5397 athletes and 518 calf/ lower leg muscle injuries. Best evidence synthesis highlights chronological age and previous history of calf strain are the strongest risk factors for future calf muscle injury. Previous lower limb injuries (hamstring, quadriceps, adductor, knee) show some limited evidence for an association. Numerous factors lack evidence of an association, including height, weight, gender and side dominance. Summary/conclusion Increasing age and previous calf strain injury are the most predictive of future calf injury. The overall paucity of evidence and the trend for studies of a high risk of bias show that further research needs to be undertaken.
Escape of Minor Histocompatibility Antigen-Restricted Anti-Leukemia Immunity Associated with Loss of Specific HLA-I Locus Expression in a Leukemia Patient after an Intensive Immunotherapy.
Authors: Lung-Ji Chang, Chun-Rong Tong, Jih-Luh Tang, Yoshiki Akatsuka, Shuhong Han, Yin Liang, Chi-Cheng Li, Lujia Dong, Tong Wu, Dao-Pei Lu
Journal: Blood (2007)
Labour urges government to boost funding for NHS and social care in budget
Authors: Gareth Iacobucci
Journal: BMJ (2017)

The government must commit £2bn (€2.3bn; $2.5bn) extra funding to social care and increase its financial offering to the NHS in England in next week’s budget to halt the alarming decline in services, Labour’s shadow health secretary has said.

Speaking at the Nuffield Trust health policy summit on Friday 3 March, Jonathan Ashworth called on the chancellor of the exchequer to bring forward the £2bn extra funding for social …
We need to talk about resuscitation
Authors: Rebecca Coombes
Journal: BMJ (2017)

Doctors are often reluctant to start conversations about resuscitation decisions. In four articles The BMJ squares up to decisions on “Do not attempt cardiopulmonary resuscitation” (DNACPR), to spark debate about an area of clinical practice often fraught with legal and ethical challenges.

Zoe Fritz and colleagues describe how doctors are hesitant to raise DNACPR in case it distresses patients or leads to a complaint (doi:10.1136/bmj.j813; doi:10.1136/bmj.j876). But patients rarely start this conversation either, even though research shows that many older …
Abstract P1-10-05: Omitting radiotherapy in women ≥ 65 years with early breast cancer and favorable histopathology after breast-conserving surgery, sentinel node biopsy and adjuvant endocrine therapy is safe
Authors: KKA Villman, Å Wickberg, F Killander, H Lindman, J Bjöhle, P Edlund, L Tennvall-Nittby, K Bachmeier, M Carlberg, C Blomqvist, J Ahlgren, G Liljegren
Journal: Cancer Research (2017)

Abstract Background: The benefit of radiotherapy in older women with endocrine responsive early breast cancer treated with breast-conserving surgery and endocrine therapy is unclear. The aim of this study was to verify if omission of radiotherapy in a predefined cohort of patients with good prognosis early breast cancer after breast conservation is safe. Methods: Eligibility criteria were: consecutive patients with age ≥ 65 years, breast-conserving surgery (sector resection + sentinel node biopsy), clear margins, unifocal T 1 N0, Elston grade 1 and 2, estrogen receptor-positive. After informed consent adjuvant endocrine therapy, either tamoxifen or an aromatase inhibitor, was prescribed for 5 years. Primary endpoint was ipsilateral breast tumor recurrence (IBTR). Secondary endpoints were contralateral breast cancer, recurrence-free survival (RFS) and overall survival (OS). Results: Between 2006 and 2012, we included 603 women from 14 Swedish centers. Two patients did not fulfill the inclusion criteria and were excluded from the analysis. Median age was 71 years (range 65 to 90). At a median follow-up of 59 months (range 2 to 110) 13 IBTR (cumulative incidence at five years, 1.3% (95% CI, 0.6% to 2.7%), 4 regional recurrences (one combined with IBTR), 2 distant recurrences both without IBTR or regional recurrence and 11 contralateral breast cancers was observed. Twenty-nine patients were diagnosed with tumors of other origin. Seven of them were endometrial cancers. There were 39 deaths. Only one of the deaths (2.6%) was due to breast cancer and 11 (28.2%) were due to other cancers (2 endometrial cancers). Five-year overall survival was 93.9% (95% CI, 91.4% to 95.7%). Conclusion: This study demonstrates, with a median follow-up of 59 months, that breast-conserving surgery and endocrine therapy without radiotherapy is a safe treatment option in women with early breast cancer and favorable histopathology aged ≥ 65 years. The risk of IBTR is comparable to the risk of contralateral breast cancer. The low rate of breast cancer deaths indicates that breast cancer mortality is of secondary importance in this subset of women. Citation Format: Villman KKA, Wickberg Å, Killander F, Lindman H, Bjöhle J, Edlund P, Tennvall-Nittby L, Bachmeier K, Carlberg M, Blomqvist C, Ahlgren J, Liljegren G. Omitting radiotherapy in women ≥ 65 years with early breast cancer and favorable histopathology after breast-conserving surgery, sentinel node biopsy and adjuvant endocrine therapy is safe [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-10-05.
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Authors: Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Claudia T Martorell, Joseph de Wet, Hans-Jürgen Stellbrink, Jean-Michel Molina, Frank A Post, Ignacio Pérez Valero, Danielle Porter, YaPei Liu, Andrew Cheng, Erin Quirk, Devi SenGupta, Huyen Cao
Journal: The Lancet HIV (2017)
Phase II trial of robotic stereotactic radiosurgery (SBRT) in patients with recurrent gynecologic malignancies.
Authors: Charles Kunos, James Brindle, Ramon Adams, Robert DeBernardo
Journal: Journal of Clinical Oncology (2012)

5102 Background: Ablative radiation dose delivered by a robotic SBRT platform has shown progression-free survival benefit in two limited case series among patients with recurrent gynecological malignancies. The therapeutic impact of SBRT on disease progression (PD) was evaluated in the recurrent setting in this phase II trial. Methods: Fifty patients with recurrent and measurable gynecologic malignancy were treated with SBRT. The cohort included patients with recurrent ovarian (n =25), endometrial (n =14), cervical (n =9), or vulvar (n =2) cancer, 1 prior chemotherapy or radiation regimen, and GOG performance status 0, 1, 2. Patients underwent image-guided SBRT in 3 daily doses of 800 cGy = 2400 cGy. SBRT planning target volumes were determined by both the radiation and gynecologic oncologist using non-contrasted CT and 18 F-FDG PET/CT overlays. The primary endpoints were 6-month clinical benefit rate (# complete response + # partial response + # stable disease without PD [by RECIST v1.0] / 50), and less than 30-day posttherapy toxicity. Results: Between July 2009 and September 2011, 50 patients were enrolled and have a median posttherapy follow-up of 9 months. At 3 months, 50% (n=25) had complete response, 46% (n=23) had partial response, and 4% (n=2) had stable disease in SBRT-targeted lesions. Twenty-six patients (52%) have had non-SBRT target PD and 18 (36%) have died of PD. Of the 50 patients, 33 had a PD-free interval of at least 6 months, for an overall clinical benefit rate of 66%. Less than 30-day posttherapy SBRT-related toxicities were grade 2 fatigue (n =9 [18%]), grade 2 nausea (n =3[6%], grade 3 nephropathy (n =2[4%]), and grade 4 hyperbilirubinemia (n =1[2%]). Conclusions: This is the first phase II clinical trial of SBRT showing a clinically relevant benefit of ablative radiation in the setting of recurrent gynecological disease. Despite excellent control of targeted lesions with minimal toxicity, non-SBRT target PD rates are high, spurring interest for future SBRT-chemotherapy clinical trials.
Adverse Events after Infusions of Cryopreserved Hematopoietic Stem Cells Depend on Non-Mononuclear Cell in Infused Suspension and on Patient Age.
Authors: Giuseppe Milone, Valeria Pinto, Salvatore Mercurio, Aurora Strano, Stefania Coppoletta, Benedetto Farsaci, Massimo Poidomani, Salvatore Leotta, Rosario Giustolisi
Journal: Blood (2006)
Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults
Authors: Willis H. Navarro, Manza-A Agovi, Brent Logan, Andrea Bacigalupo, Karen K Ballen, Brian J. Bolwell, Haydar Frangoul, Vikas Gupta, Theresa Hahn, Mark Juckett, Hillard M. Lazarus, Mark R. Litzow, Jane Liesveld, Jan Moreb, David Marks, Philip L. McCarthy, J. Douglas Rizzo
Journal: Blood (2008)
PP85. CAVERNOMA AS A BENIGN VASCULAR MALFORMTION: IS IT TIME FOR A RETHINK?
Authors: Mr Giannis Sokratous, Mr Ismail Ughratdar, Mr Richard Selway, Prof Safa Al-Sarraj, Prof Keyoumars Ashkan
Journal: Neuro-Oncology (2017)

INTRODUCTION: Rapid growth in cerebral cavernous malformation is rare. We present the case of a 71 year old patient with known multiple cavernomas over many years in whom one lesion showed rapid expansion in size. Histological examination revealed co-existence of glioblastoma within the cavernoma. We review the literature for similar cases and discuss the potential mechanisms underlying this transformation. METHODS: Review of the literature though databases MEDLINE, EMBASE, PubMed and Google scholar was performed using keywords glioma, cavernoma and collision tumour. RESULTS: Three cases were identified in the literature with known cerebral cavernous malformations that transformed to glioblastoma multiforme. All cases were female with imaging confirming rapid growth in the lesion. CONCLUSION: Although rare, rapid expansion of existing cavernoma should be treated as suspicious for transformation into other tumour types.
Multitarget Antileukemic Effects of Metformin in Myeloproliferative Neoplasm Cells: Inhibition of JAK2/STAT Signaling and Mitochondrial Activity
Authors: João Agostinho Machado-Neto, Bruna Alves Fenerich, Renata Scopim-Ribeiro, Carlos Roberto Porto Dechandt, Ana Paula Nunes Rodrigues Alves, Jaqueline Cristina Fernandes, Priscila Santos Scheucher, Belinda Pinto Simões, Luciane Carla Alberici, Lorena Lôbo de Figueiredo Pontes, Eduardo Magalhães Rego, Fabiola Traina
Journal: Blood (2016)
Fetal Loss Associated With Excess Thyroid Hormone Exposure—Reply
Authors: Samuel Refetoff, Roy E. Weiss, João Anselmo
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
알코올간질환 환자에서 간경변 진단을 위한 transient elastography의 유용성
Authors: 김상균, Young Seok Kim, Soung Won Jeong, Hee Kyung Kim, Jang Jae Young, 문종호, Kim，Hong-Soo, Joon Seong Lee, 이문성, Chan Sup Shim, Boo Sung Kim
Journal: Clinical and Molecular Hepatology (2009)

배경/목적: 알코올간경변은 일반적으로 여러 가지 임상적 특징을 종합하여 진단하게 되지만 진단적 정확도가 낮고, 특히 간내 지방 변성으로 인하여 방사선 영상 진단이 용이하지 않다. Transient elastography(Fibroscan(R), Echosens, France)는 간조직의 탄성률을 측정하여 간섬유화의 정도를 비침습적으로 추정하는 장비이다. 최근 여러 문헌에서 transient elastography를 이용한 간탄성률 측정이 바이러스간경변의 섬유화의 정도를 감별하는데 매우 유용하다고 보고하고 있지만 알코올간경변증의 진단에 있어 임상적 유용성에 대해서는 보고가 적다. 저자들은 간조직검사를 시행한 알코올간질환 환자에서 간경변증의 진단방법으로 transient elastography를 이용한 간탄성률 측정의 유용성을 알아보고 간초음파, APRI index의 진단능과 비교하였다. 대상/방법: 하루 80 g 이상의 음주력이 있는 알코올간질환 환자 45명을 대상으로 간초음파소견, 간탄성률 측정치, APRI index 및 기타 임상적 변수와 조직검사상 간섬유화 단계와의 상관성을 분석하고, ROC곡선의 AUC를 구하여 간경변증에 대한 각 변수의 예측 능력을 평가하였다. 간섬유화의 진행은 대한병리학회 소화기병리연구회의 체계에 따라 0~4단계로 분류했다. 결과: 섬유화 단계에 따른 간탄성률 수치의 중간값을 보면 F1(5명)에서 5.6(범위: 4.8~6.1) kPa, F2(4명)에서 11.5(7.2~19.0) kPa, F3(7명)에서 18.5(9.0~27.7) kPa, F4(29명)에서 35.0(22.8~66.5) kPa이었다. 간섬유화와 유의한 연관성을 보이는 변수는 혈청 내 알부민, 총 빌리루빈, AST 수치와 프로트롬빈시간, 혈소판 수치였다. 간섬유화의 각 단계별로 간탄성률 측정값의 평균을 비교하였을 때 F1과 F2, 3 사이에 유의한 차이가 있었고, F4와 다른 간섬유화 등급간에 유의한 차이를 보였다(P<0.001). 간초음파검사의 간경변 진단의 민감도는 66%, 특이도는 94%였다. 간탄성률 측정을 이용한 간경변(F4) 및 진행성 간섬유화(≥F3)의 예측의 AUC값은 각각 0.97(95% CI: 0.93~1.01), 0.98(95% CI: 0.94~1.02)로 매우 높은 결과를 보였다. 또한 간경변 예측을 위한 적절한 간탄성률 기준값은 25.8 kPa이었으며, 이 때 민감도와 특이도는 90%와 87%였다. 결론: Transient elastography를 이용한 간탄성률 측정은 알코올간질환 환자에서 간섬유화의 정도를 파악하고 간경변을 진단하는 데 도움이 될 수 있을 것으로 생각한다.
Abstract P3-03-11: Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1
Authors: Q Liu, Y Zhu, Y Liu
Journal: Cancer Research (2017)

Abstract Tamoxifen is the most widely used endocrine therapy in estrogen receptor (ER)- positive breast cancer patients. Tamoxifen resistance has been a major clinical problem and is accountable for relapse in about one third of these patients. Most of these recurrent patients will inevitably receive chemotherapy. However, the association between tamoxifen-resistance and chemosensitivity in breast cancer has never been explored. We found that both mRNA and protein expression of BARD1 and BRCA1 were significantly upregulated in tamoxifen-resistant MCF7 and T47D breast cancer cell lines, when compared with their parental lines. Furthermore, the tamoxifen-resistant cells were markedly more resistant to DNA-damaging chemotherapy including cisplatin and doxorubicin, but not to paclitaxel. Silencing BARD1 or BRCA1 by siRNAs or inhibition of BRCA1 phosphorylation by Dinaciclib restored the sensitivity to cisplatin and doxorubicin in tamoxifen-resistant cells. In addition, we identified that activated PI3K/AKT/ERK pathway in tamoxifen-resistant cells was responsible for the upregulation of BARD1 and BRCA1. BKM120, a PI3K inhibitor, decreased the expression of BARD1 and BRCA1 in tamoxifen-resistant cells and re-sensitized them to cisplatin and doxorubicin both in vitro and in xenografted mice. More importantly, higher BARD1 expression was significantly associated with poorer prognosis in breast cancer patients. BARD1 and BRCA1 were also significantly upregulated in recurrent breast cancer samples after tamoxifen compared with their primary counterparts. These results indicate an important role of BARD1 and BRCA1 in the chemoresistance of ER-positive breast cancer. Targeting PI3K/Akt pathway or BRCA1 phosphorylation may help to overcome the resistance to DNA-damaging chemotherapy in these tumors. Citation Format: Liu Q, Zhu Y, Liu Y. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1 [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-03-11.
Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy
Authors: Monica Bocchia, Lara Aprile, Santina Sirianni, Elisabetta Abruzzese, Antonella Gozzini, Fausto Castagnetti, Luca Puccetti, Federica Sorà, Sara Galimberti, Anna Sicuranza, Mario Tiribelli, Massimo Breccia, Alessandra Iurlo, Giulia Bartalucci, Daniele Cattaneo, Olga Mulas, Claudia Baratè, Giovanni Caocci, Simona Sica, Gianantonio Rosti, Alberto Bosi, Donatella Raspadori
Journal: Blood (2016)
Epoxyeicosatrienoic Acids Regulate Hematopoietic Stem/Progenitor Cell Fate Decision During Stress Response and Embryonic Hematopoiesis
Authors: Pulin Li, Emily K Pugach, Elizabeth B Riley, Dipak Panigrahy, Garrett C Heffner, Teresa V. Bowman, Owen J. Tamplin, Shannon McKinney-Freeman, Thorsten M Schlaeger, George Q. Daley, Darryl C Zeldin, Leonard I. Zon
Journal: Blood (2011)
Subject Index Vol. 72, 2003
Authors: Franco Benazzi, Masayo Kojima, Yoshihiro Senda, Teruo Nagaya, Shinkan Tokudome, Gudrun Schneider, Georg Driesch, Andreas Kruse, Michael Wachter, Hans-Georg Nehen, Gereon Heuft, Willeke H. van Zelst, Edwin de Beurs, Aartjan T.F. Beekman, Dorly J.H. Deeg, Richard van Dyck, Peter Tyrer, Tom Sensky, Sarah Mitchard, David Healy, David MacLean, Chiara Rafanelli, Renzo Roncuzzi, Livio Finos, Eliana Tossani, Elena Tomba, Lara Mangelli, Stefano Urbinati, Giuseppe Pinelli, Giovanni A. Fava, Zoltán Rihmer, Franco Benazzi, Angelo Picardi, Mohammad Reza Namazi, Richard Balon, Karina W. Davidson, Paul Rowan, Cheryl Barksdale, Toshiaki A. Furukawa, Michael William MacGregor
Journal: Psychotherapy and Psychosomatics (2003)
Role for NLRP3 Inflammasome–mediated, IL-1β–Dependent Responses in Severe, Steroid-Resistant Asthma
Authors: Richard Y. Kim, James W. Pinkerton, Ama T. Essilfie, Avril A. B. Robertson, Katherine J. Baines, Alexandra C. Brown, Jemma R. Mayall, M. Khadem Ali, Malcolm R. Starkey, Nicole G. Hansbro, Jeremy A. Hirota, Lisa G. Wood, Jodie L. Simpson, Darryl A. Knight, Peter A. Wark, Peter G. Gibson, Luke A. J. O’Neill, Matthew A. Cooper, Jay C. Horvat, Philip M. Hansbro
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Severe, steroid-resistant asthma is the major unmet need in asthma therapy. Disease heterogeneity and poor understanding of pathogenic mechanisms hampers the identification of therapeutic targets. Excessive nucleotide-binding oligomerization domain-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome and concomitant IL-1β responses occur in chronic obstructive pulmonary disease, respiratory infections, and neutrophilic asthma. However, the direct contributions to pathogenesis, mechanisms involved, and potential for therapeutic targeting remain poorly understood, and are unknown in severe, steroid-resistant asthma.